| Scrip Code | 524348 |
|---|---|
| NSE Symbol | AARTIDRUGS |
| MSEI Symbol | NOTLISTED |
| ISIN | INE767A01016 |
| Name of company | AARTI DRUGS LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 03-02-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 27-01-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Third quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Pharmaceuticals |
| Start date and time of board meeting | 03-02-2026 14:45:00 |
| End date and time of board meeting | 03-02-2026 17:10:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 60,171.00 | 1,84,501.00 | |
| Other income | 123.00 | 163.00 | |
| Total income | 60,294.00 | 1,84,664.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 33,452.00 | 1,07,683.00 |
| (b) | Purchases of stock-in-trade | 2,251.00 | 8,177.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 2,961.00 | 972.00 |
| (d) | Employee benefit expense | 3,316.00 | 9,703.00 |
| (e) | Finance costs | 929.00 | 2,556.00 |
| (f) | Depreciation, depletion and amortisation expense | 1,795.00 | 4,893.00 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 12,688.00 | 36,626.00 |
| Total other expenses | 12,688.00 | 36,626.00 | |
| Total expenses | 57,392.00 | 1,70,610.00 | |
| 3 | Total profit before exceptional items and tax | 2,902.00 | 14,054.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 2,902.00 | 14,054.00 |
| 6 | Tax expense | ||
| 7 | Current tax | (1,349.00) | (441.00) |
| 8 | Deferred tax | 196.00 | 527.00 |
| 9 | Total tax expenses | (1,153.00) | 86.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 4,055.00 | 13,968.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 4,055.00 | 13,968.00 |
| 17 | Other comprehensive income net of taxes | 31.00 | 43.00 |
| 18 | Total Comprehensive Income for the period | 4,086.00 | 14,011.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 4,054.00 | 13,972.00 | |
| Total profit or loss, attributable to non-controlling interests | 1.16 | (4.51) | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | 4,083.00 | 14,013.00 | |
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 2.73 | (2.38) | |
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 9,127.00 | 9,127.00 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 4.44 | 15.3 | |
| Diluted earnings (loss) per share from continuing operations | 4.44 | 15.3 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 4.44 | 15.3 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 4.44 | 15.3 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes : 1. The above results for the Quarter & Period ended 31st December, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 3rd February, 2026. 2. The Board of Directors have declared interim Dividend of Rs.2.00/-( Rupee Two) per Equity Share of Rs. 10/- each (20%) amounting to Rs.18,25,40,000 for the Period ended 31st December,2025. 3. As on December 31, 2025 the Company, has 3 (three) subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, Pinnacle Chile SpA and 1 (one) step down subsidiary, namely Pharma Go SpA. 4. The company has completed the buyback of 6,65,000 equity shares of face value of Rs.10/- representing up to 0.72% of the total number of Equity Shares of the Company at a price of Rs. 900/- per Equity Share (including premium of Rs. 890/- per Equity Share) payable in cash for an aggregate amount of up to Rs. 59,85,00,000/- (excluding filing fees payable to the SEBI, advisors’ fees, stock exchanges fee for usage of their platform for Buyback, transaction costs viz. brokerage, applicable taxes inter alia including Buyback tax, securities transaction tax, GST, stamp duty, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses etc.)(“Buyback Size”) on September 24, 2024. Post buyback Paid up Share Capital of the Company reduced to Rs. 91,27,00,000 divided into 9,12,70,000 Equity Shares of Rs.10/- each. 5. On November 21, 2025, the Government of lndia notified the four Labour Codes - the Code on Wages, 2019, the lndustrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment has also published draft Central Rules and FAQs on aforesaid labour codes. The detailed impact assessment is currently in progress, necessary adjustments, if any, will be identified and appropriately accounted for in Q4 FY 2025–26. 6. Company has only one business segment i.e. pharmaceuticals. 7. The Company’s new manufacturing plant at Sayakha, Gujarat has commenced commercial production/operations w.e.f. September 4, 2025. 8. Figures for the previous Quarter have been regrouped or rearranged wherever necessary. 9. The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors. FOR AARTI DRUGS LIMITED Sd/- Prakash M. Patil DIN: 00005618 (Chairman, Managing Director & CEO) Place: Mumbai Date: 3rd February, 2026 |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-10-2025 | 01-04-2025 | |||||
| Date of end of reporting period | 31-12-2025 | 31-12-2025 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-10-2025 | 01-04-2025 |
| B | Date of end of reporting period | 31-12-2025 | 31-12-2025 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Foreign currency translation reserve | 31.00 | 43.00 |
| Total Amount of items that will not be reclassified to profit and loss | 31.00 | 43.00 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | ||
| 5 | Total Other comprehensive income | 31.00 | 43.00 |